Bedrijfsoverzicht
Butterfly Network, Inc. is a specialized enterprise within the healthcare sector, specifically focused on the medical devices industry, where it develops, manufactures, and commercializes ultrasound imaging solutions for use in the United States and international markets. The company's product portfolio centers on the Butterfly iQ+ and iQ3 ultrasound devices, which are engineered to perform whole-body imaging using a single handheld probe that integrates directly into clinical workflows. This operational scale is reflected in a total market capitalization of $1.05B, supported by annual revenue of $97.61M and a workforce comprising 220 employees. These valuation and revenue figures indicate that the company operates as a mid-cap entity in the medical technology space, possessing a significant asset base relative to its current income generation but maintaining a lean operational footprint that suggests high specialization rather than broad-market dominance. The concentration of resources into handheld imaging technology positions the firm to capture niche demand for point-of-care diagnostics, though the market cap also signals that the broader market has priced in significant risks regarding its path to profitability given the current financial structure.
Financiële gezondheid
The financial performance of Butterfly Network, Inc. for the trailing twelve months shows revenue of $97.61M, net income of -$77,064,000, and EBITDA of -$54,158,000, revealing a substantial gap between top-line growth and bottom-line profitability that highlights a cost structure with heavy operating expenses or investment in growth initiatives that are not yet yielding positive net results. Despite the negative net income, the company demonstrates financial flexibility through a positive free cash flow of $12.72M, which suggests that operational cash generation is sufficient to cover capital expenditures and potentially fund ongoing R&D or expansion without immediate external financing. The margin analysis displays a gross margin of 64.7%, indicating efficient production and pricing power for the ultrasound devices, contrasted sharply by an operating margin of -36.1% and a profit margin of -79.0%, which collectively indicate that significant operating costs are consuming the gross profits before reaching the bottom line. On the balance sheet, the company holds $150.49M in cash against $20.40M in debt, resulting in a debt-to-equity ratio of 10.41, which presents a complex picture where high leverage metrics coexist with a conservative liquidity posture driven by abundant cash reserves. This liquidity is further confirmed by a current ratio of 3.83, indicating that the company possesses 3.83 times the current assets necessary to cover its short-term liabilities, thereby mitigating immediate solvency concerns despite the high debt-to-equity figure. Finally, the return metrics show a return on equity of -42.2% and a return on assets of -13.2%, which reveal that management has not yet been effective in generating positive returns on the shareholder capital or the total asset base, a common characteristic for pre-profitability growth-stage companies in the medical device sector.
Waarderingsbeoordeling
The valuation metrics for Butterfly Network, Inc. present a challenging picture with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E stands at -41.10, implying that the market is pricing in significant future earnings recovery or that the current valuation model relies heavily on sales growth rather than immediate profitability. The price-to-book ratio is 5.32, which indicates that the market is valuing the company at more than five times its book value, suggesting a premium assigned to its intellectual property and growth potential despite the lack of current earnings. Alternative valuation metrics such as the price-to-sales ratio of 10.72 and an EV/EBITDA of -16.92 suggest that the stock is priced significantly above its historical revenue multiples and earnings generation, reflecting high expectations for future scaling that must be realized to justify the current market price. The stock price has exhibited substantial volatility, trading between a 52-week low of $1.32 and a 52-week high of $5.03, meaning the current valuation sits somewhere within a wide historical range that reflects the binary nature of investor sentiment toward its turnaround story. The beta of 2.22 indicates that the stock's price volatility is more than twice that of the broader market, highlighting the heightened risk profile associated with investing in a small-cap medical device company with negative earnings.
Growth & Income
The company reports a robust revenue growth rate of 41.0% year-over-year, while earnings growth is marked as N/A due to the company's loss-making status, implying that the top-line expansion is currently the sole driver of value creation before profitability is achieved. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which explains that the firm retains all generated cash to reinvest into product development, manufacturing scale, and market expansion rather than distributing income to shareholders. This strategy of reinvesting earnings aligns with the growth profile of a company in the medical devices industry that requires continuous capital expenditure to maintain its technological edge in ultrasound imaging solutions. The overall growth and income profile is characterized by aggressive revenue expansion funded internally by strong free cash flow, yet tempered by the absence of current earnings and a high degree of price volatility relative to the broader market.